关键词 | 全球政策进展 |工信部|高性能反应器|中试平台 【SynBioCon】 获 悉 ，本月， 工信部 接连发布两项关于生物制造相关文件，涉及高性能生物反应器和生物制造中试平台建设，进一步推进了这一新 质生产力的产业进展。 11月4日，工信部消费品司发布了 《关于高性能生物反应器创新任务入围揭榜单位名单的公示 》 的通知 ，其 中有 9个关键 高性能生物反应 器 ， 共 有 23个牵头高 校科研院所和企业 入围揭榜单位。 分别是沃美生物、中国科学院天津工生所、华东理工、迪比尔生物、艾贝泰生物、楚天生物、东富龙、华 龛生物、中国科 学院过程所、百林科新材 料、 微基智慧科技、 中国科学院上海微系统与信息技术研究所、烁谱科技、长城搅拌器设备股份、楚天科技、川 宁生物、舜宇恒平科学仪器、瑞莱谱 （杭州）、国科新智（天津）、 中国科学院苏州生物医学工程技术研究所、 镇江东方生物工程、 艾力特生物科技、 成都英德生物医药。 11月10日， 工信部消费品司发布了 《 生物制造中试能力建设平台名单（第一批）公 示》 的通知。公布了共有 43家单位 入围 生物制造中试能力建设 平台。 其中4颗星以上评级的中试平台单位有 ...

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has announced the list of selected units for the high-performance bioreactor innovation task, aiming to enhance the supply capacity of key equipment for biological manufacturing [2][3]. Summary by Relevant Sections Task Objectives - The initiative focuses on three categories: reactor systems, key components and consumables, and industrial operating systems, with a total of nine tasks aimed at selecting and nurturing units with strong innovation capabilities and mastery of core technologies [2]. Selected Units - Notable units included in the list are: - Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences - Guangzhou Aibaitai Biotechnology - Shanghai Dongfulong - Jiangsu Weiji Wisdom - Shanghai Shunyu Hengping - Shanghai Ailite [5][6]. Task Directions - The tasks cover various directions such as: 1. Microbial parallel bioreactors 2. Cell parallel bioreactors 3. Large cell bioreactors 4. Core physicochemical parameter in-situ monitoring 5. Biological reactor intelligent industrial operating systems [5][6]. Innovation Goals - The goal is to break through several landmark technologies, cultivate typical application scenarios, and accelerate the landing and application of new technologies and products, thereby enhancing the integrated development capability of high-performance bioreactors [2].

新华财经上海11月7日电 （谷青竹） 11月6日，维昇药业首次以展商身份亮相进博会，在临港展示区完成两项重磅签约：与本土制药装备龙头东富龙达成双 腔冻干制剂技术战略合作，与临港新片区管委会、临港集团物贸平台签署产业协同协议。 维昇药业执行董事兼首席执行官卢安邦表示，进博会不仅是展示全球创新的舞台，更是链接产业上下游、促成高水平合作的重要平台。此次双签约的达成， 标志着其"全球创新、中国加速"战略的进一步落地，也为生物医药领域"全球创新药品"与"中国高端制造"的"双向奔赴"写下生动注脚。 双腔冻干技术强强联合 破解行业核心痛点 本次维昇药业与东富龙的战略合作，核心聚焦双腔冻干制剂技术的研发与产业化，直指高端生物制剂领域"稳定性与使用便捷性难以兼得" 的行业痛点。作 为保障高端生物制剂品质的关键技术，双腔冻干制剂通过创新设计，实现了药物粉末与稀释剂在密闭系统中的独立存储，从根源上解决了传统制剂的诸多局 限。 维昇药业核心产品隆培生长激素（lonapegsomatropin）成为该技术的重要应用载体。借助双腔冻干技术，该产品在无需添加防腐剂的条件下，实现≤30℃室 温环境下长达6个月的稳定保存；在使用场景中，患者无 ...

Market Overview - The medical device sector experienced a slight decline of 0.1% on November 3, with Botao Bio leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Top Performers - N Danna saw a significant increase of 497.08%, closing at 102.10 with a trading volume of 67,900 shares and a transaction value of 665 million [1] - Weigao Blood Purification rose by 10.01%, closing at 42.30 with a trading volume of 11,500 shares [1] - Chutian Technology increased by 7.95%, closing at 12.09 with a trading volume of 829,300 shares and a transaction value of 978 million [1] Underperformers - Botao Bio led the decline with a drop of 8.32%, closing at 42.73 with a trading volume of 62,700 shares and a transaction value of 266 million [2] - ZhenDe Medical fell by 5.61%, closing at 89.67 with a trading volume of 289,000 shares [2] - Zhongke Meiying decreased by 3.99%, closing at 21.41 with a trading volume of 24,700 shares [2] Capital Flow - The medical device sector saw a net inflow of 300 million from institutional investors, while retail investors experienced a net outflow of 415 million [2][3] - Notable net inflows from institutional investors included ZhenDe Medical with 312 million and Furuishi with 69.51 million [3] - Retail investors showed significant outflows in stocks like Chutian Technology and East Fortune, with outflows of 4.48 million and 1.12 billion respectively [3]

Core Insights - The article highlights the significant actions of well-known private equity fund managers in the third quarter, particularly their increased investments in the electronic and biopharmaceutical sectors, as well as quality stocks that are expected to reverse their fortunes [1][4]. Private Equity Fund Activities - As of October 29, 31 private equity managers with over 10 billion yuan in assets have appeared in the top ten shareholders of A-share listed companies, with a total holding value exceeding 30 billion yuan [2]. - Notable fund managers such as Feng Liu from Gao Yi Asset and Dong Chengfei from Rui Jun Asset have made substantial new investments in companies like Dongfulong and Dinglong Technology, respectively [2][5]. - The biopharmaceutical sector has seen increased interest, with several top private equity firms boosting their stakes in companies like Kangzhong Medical and Dong'e Ejiao [4]. Company Performance - Dongfulong reported a revenue of approximately 3.704 billion yuan for the first three quarters, a year-on-year increase of 6.14%, while its net profit attributable to shareholders decreased by 13.86% to about 132 million yuan [3]. - Dinglong Technology achieved a total revenue of 2.698 billion yuan, reflecting a year-on-year growth of 11.23%, and a net profit of 519 million yuan, up 38.02% [6]. - Rabbit Baby, a comprehensive service provider for indoor decoration materials, reported a revenue of 2.684 billion yuan, a 5.03% year-on-year increase, and a net profit of 361 million yuan, up 51.67% [12]. Sector Trends - The biopharmaceutical industry, particularly innovative drugs, has shown strong performance due to low valuations and increasing global competitiveness of Chinese pharmaceutical companies [4]. - The technology sector, including electronics and computing, remains a favored investment area for private equity managers, with significant new positions taken in companies like Yangjie Technology [5][7]. - The overall market for private equity heavyweights is concentrated in 25 primary industries, with the computer sector being the largest, holding a total value of approximately 1.067 billion yuan across 12 stocks [9][10].

Core Viewpoint - The recent quarterly reports from listed companies reveal a significant shift in investment strategies among prominent private equity managers, with an increased focus on cyclical industries and a need to monitor fundamental developments, policy benefits, and industrial upgrades as core themes [1][4]. Private Equity Holdings - Gao Yi Asset's Feng Liu significantly reduced holdings in Hikvision by 58 million shares, retaining 280 million shares valued at 8.826 billion yuan, making it the fourth-largest shareholder [1]. - Renqiao Asset's Xia Junjie maintained positions in several stocks while slightly reducing holdings in Xingfu Electronics and increasing stakes in Beijing Renli [1]. - Ningquan Asset's Yang Dong entered as the eighth-largest shareholder in Fuanna with 6.0512 million shares valued at 4.2 million yuan [2]. - Ruijun Asset's funds became top shareholders in Dinglong Co., while also increasing stakes in other companies [2]. Increased Focus on Cyclical Industries - Gao Yi Asset's Deng Xiaofeng reduced holdings in Zijin Mining by approximately 18.6 million shares, still holding 180 million shares valued at 5.3 billion yuan, with a significant gain of about 1.5 billion yuan from the position [3]. - The same fund also reduced its stake in Yun Aluminum, holding 28.5 million shares valued at 1.164 billion yuan [3]. Policy Benefits and Industrial Upgrades - The Shanghai Composite Index surpassed 4,000 points, reflecting improved market sentiment and recognition of the value reassessment cycle in Chinese equity assets [4]. - Fengjing Capital noted that economic data remains resilient, with expectations for moderate improvement in fixed investment growth due to policy initiatives [4]. - Ning Shui Capital emphasized the importance of policy benefits and industrial upgrades as core investment themes while advising caution regarding high valuations [4].

Core Insights - Dongfulong reported a revenue of 1,275,302,744.60 yuan for Q3 2025, representing a year-on-year growth of 6.39% [1] - The net profit attributable to shareholders reached 85,657,239.71 yuan, showing a significant year-on-year increase of 120.91% [1]

Core Viewpoint - Dongfulong (300171.SZ) reported a revenue of 3.704 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 6.14% [1] - The net profit attributable to shareholders decreased by 13.86% to 132 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 20.15% to 105 million yuan [1] - Basic earnings per share stood at 0.1729 yuan [1] Financial Performance - Revenue for the first three quarters: 3.704 billion yuan, up 6.14% year-on-year [1] - Net profit attributable to shareholders: 132 million yuan, down 13.86% year-on-year [1] - Net profit after non-recurring items: 105 million yuan, down 20.15% year-on-year [1] - Basic earnings per share: 0.1729 yuan [1]

Group 1 - Dongfulong (SZ 300171) announced on October 28 that it will recognize an asset impairment provision, which will reduce the company's total profit for Q3 2025 by approximately 130 million yuan [1] - The asset impairment provision has not been confirmed by an audit [1] - For the year 2024, Dongfulong's revenue composition is as follows: 99.84% from specialized equipment manufacturing and 0.16% from services [1] Group 2 - As of the report, Dongfulong's market capitalization is 12.4 billion yuan [2]

Market Overview - On October 28, the medical device sector rose by 0.21%, led by Chutian Technology, while the Shanghai Composite Index closed at 3988.22, down 0.22%, and the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Top Performers - Chutian Technology (300358) closed at 11.32, with a significant increase of 20.04% and a trading volume of 842,800 shares, amounting to a transaction value of 924 million yuan [1]. - Libang Instruments (300206) saw a closing price of 13.97, up 15.45%, with a trading volume of 521,600 shares and a transaction value of 718 million yuan [1]. - Zhend Medical (603301) closed at 80.95, increasing by 10.00%, with a trading volume of 159,900 shares [1]. Underperformers - Sino Medical (688108) experienced a decline of 9.39%, closing at 25.19, with a trading volume of 415,300 shares and a transaction value of 1.084 billion yuan [2]. - Yingke Medical (300677) closed at 38.56, down 8.58%, with a trading volume of 333,700 shares [2]. - Nanwei Medical (688029) saw a decrease of 6.30%, closing at 81.52, with a trading volume of 56,100 shares [2]. Capital Flow - The medical device sector experienced a net outflow of 405 million yuan from institutional investors, while retail investors saw a net inflow of 417 million yuan [2][3]. - Chutian Technology had a net inflow of 162.16 million yuan from institutional investors, while retail investors had a net outflow of 64.44 million yuan [3]. - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are actively buying [2][3].